TRAVASOL 10% W/O ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 10% W/O ELECTROLYTES (TRAVASOL 10% W/O ELECTROLYTES).

How it works

Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and urea cycle in the liver. Carbon skeletons enter the Krebs cycle or are used for gluconeogenesis. Nitrogen is converted to urea.
Excretion	Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Half-life	The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Protein binding	Amino acids are not significantly bound to plasma proteins (<10%). Electrolytes have negligible protein binding (<5%).
Volume of Distribution	Amino acids distribute widely, with apparent Vd of 0.4-0.6 L/kg, reflecting total body water. Clinical meaning: Indicates rapid distribution into extracellular and intracellular spaces.
Bioavailability	Intravenous: 100% bioavailable. Not administered orally or via other routes due to design for parenteral nutrition.
Onset of Action	Intravenous infusion: Immediate metabolic utilization, with plasma amino acid levels rising within minutes. Clinical effects (e.g., nitrogen balance improvement) are observed within hours.
Duration of Action	After cessation of infusion, plasma concentrations decline rapidly (half-life 1-2 hours). Clinical effects on nitrogen balance persist for several hours as amino acids are incorporated into protein synthesis. Duration is infusion-dependent; short-term effects last 2-4 hours after stopping.

Classification & Brands

Dosing & administration

10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.

Dosage form	INJECTABLE
Renal impairment	GFR < 50 mL/min: restrict to 0.5-0.8 g/kg/day; GFR < 15 mL/min: 0.5 g/kg/day or avoid if not on dialysis.
Liver impairment	Child-Pugh class B/C: use with caution, avoid in hepatic encephalopathy; consider branched-chain amino acid formulas instead.
Pediatric use	Neonates: start 0.5-1 g/kg/day, increase by 0.5 g/kg/day up to 2-3 g/kg/day; older children: 1-2 g/kg/day; monitor serum amino acids.
Geriatric use	Reduce initial dose to 0.5-0.8 g/kg/day due to decreased renal function; monitor fluid balance and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 10% W/O ELECTROLYTES (TRAVASOL 10% W/O ELECTROLYTES).

Breastfeeding	Excretion into breast milk is unknown. Because amino acids are normal constituents of milk, risk is considered low. Caution is advised; no M/P ratio available.
Teratogenic Risk	No known teratogenic risk. Amino acid solutions are essential nutrients and not associated with fetal malformations when used as indicated. However, safety in pregnancy has not been systematically studied; use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Side Effect Profile

Serious Effects

Absolute Contraindications

Known hypersensitivity to any component. Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria). Severe acidosis. Anuria or severe renal impairment. Uncompensated heart failure. Acute pulmonary edema.

Clinical Precautions

Precautions

Monitor for signs of hyperammonemia, metabolic acidosis, and fluid/electrolyte imbalances. Use with caution in patients with renal impairment, hepatic failure, or congestive heart failure. Risk of infection due to catheter-related complications. Do not administer if solution is discolored or contains particulates.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 10% W/O ELECTROLYTES

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 10% W/O ELECTROLYTES (TRAVASOL 10% W/O ELECTROLYTES).

How it works

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and urea cycle in the liver. Carbon skeletons enter the Krebs cycle or are used for gluconeogenesis. Nitrogen is converted to urea.
Excretion	Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Half-life	The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Protein binding	Amino acids are not significantly bound to plasma proteins (<10%). Electrolytes have negligible protein binding (<5%).
Volume of Distribution	Amino acids distribute widely, with apparent Vd of 0.4-0.6 L/kg, reflecting total body water. Clinical meaning: Indicates rapid distribution into extracellular and intracellular spaces.
Bioavailability	Intravenous: 100% bioavailable. Not administered orally or via other routes due to design for parenteral nutrition.
Onset of Action	Intravenous infusion: Immediate metabolic utilization, with plasma amino acid levels rising within minutes. Clinical effects (e.g., nitrogen balance improvement) are observed within hours.
Duration of Action	After cessation of infusion, plasma concentrations decline rapidly (half-life 1-2 hours). Clinical effects on nitrogen balance persist for several hours as amino acids are incorporated into protein synthesis. Duration is infusion-dependent; short-term effects last 2-4 hours after stopping.

Classification & Brands

Dosing & administration

10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.

Dosage form	INJECTABLE
Renal impairment	GFR < 50 mL/min: restrict to 0.5-0.8 g/kg/day; GFR < 15 mL/min: 0.5 g/kg/day or avoid if not on dialysis.
Liver impairment	Child-Pugh class B/C: use with caution, avoid in hepatic encephalopathy; consider branched-chain amino acid formulas instead.
Pediatric use	Neonates: start 0.5-1 g/kg/day, increase by 0.5 g/kg/day up to 2-3 g/kg/day; older children: 1-2 g/kg/day; monitor serum amino acids.
Geriatric use	Reduce initial dose to 0.5-0.8 g/kg/day due to decreased renal function; monitor fluid balance and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 10% W/O ELECTROLYTES (TRAVASOL 10% W/O ELECTROLYTES).

Breastfeeding	Excretion into breast milk is unknown. Because amino acids are normal constituents of milk, risk is considered low. Caution is advised; no M/P ratio available.
Teratogenic Risk	No known teratogenic risk. Amino acid solutions are essential nutrients and not associated with fetal malformations when used as indicated. However, safety in pregnancy has not been systematically studied; use only if clearly needed.
Fetal Monitoring